Remarkably, the viability of MCF-7 D538G cells treated with Dex was reduced more than treatment with vehicle but also more than Fulvestrant (Fig. EV6A), reinforcing the clinical potential of GR activation as an estrogen receptor silencer (ERS) in ESR1 mutant breast cancer. This evidence concerns the gene NR3C1 and breast carcinoma.